- Home
- FBRT vs PHAT Comparison
FBRT vs PHAT Comparison
Compare FBRT & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FBRT | PHAT |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 882.8M | 894.0M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | FBRT | PHAT |
|---|---|---|
| Price | $8.58 | $10.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $13.50 | ★ $19.50 |
| AVG Volume (30 Days) | ★ 1.2M | 986.5K |
| Earning Date | 04-27-2026 | 04-30-2026 |
| Dividend Yield | ★ 16.61% | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $12.34 | $92.15 |
| Revenue Next Year | $4.95 | $59.79 |
| P/E Ratio | $13.56 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $8.40 | $2.21 |
| 52 Week High | $13.15 | $18.31 |
Technical Indicators
Market Signals| Indicator | FBRT | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 34.04 | 44.34 |
| Support Level | $8.42 | $10.06 |
| Resistance Level | $9.23 | $12.77 |
| Average True Range (ATR) | 0.24 | 0.63 |
| MACD | -0.04 | 0.07 |
| Stochastic Oscillator | 12.23 | 40.00 |
Price Performance
Historical ComparisonAbout FBRT Franklin BSP Realty Trust Inc.
Franklin BSP Realty Trust Inc is a private real estate investment trust that originates, acquires, and manages a diversified portfolio of commercial real estate debt, and first mortgage loans. secured by properties located in the United States. Its segments include the real estate debt business; the real estate securities business; the real estate owned business; and the commercial real estate conduit business.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.